LAKEWOOD, CO, U.S.A. – Terumo Blood and Cell Technologies, a medical technology company, today announces that Jackie Kunzler is the newly appointed Senior Vice President, Research and Development (R&D). She will serve on the Executive Management Committee.
Kunzler joins Terumo Blood and Cell Technologies (Terumo BCT) from Baxter Healthcare. Throughout her career, she has held successive leadership roles in healthcare, including as Baxter Healthcare's Senior Vice President for Quality and Regulatory and Head of Global Life Sciences.
Terumo BCT specializes in products that collect, separate and process blood and cells. Innovation and development are at the forefront of Terumo BCT's efforts. The company's forward-looking innovation is leading the way for unlocking the potential of blood and cell collections in varied sectors, including blood banking, plasma-based therapies and cell and gene therapies.
Kunzler has over 20 years of experience leading R&D teams and business model innovation. At Terumo BCT, she will focus on collaborative business decisions while fostering the company's culture of continuous improvement to bring a deep understanding of customers' and patients' needs to positively impact healthcare. Today, Terumo BCT's products touch at least one patient's life every minute of every day.
"Jackie has helped organizations execute complex and innovative projects with efficiency, rigor and broad systems thinking throughout her career. She brings an ability to apply her broad expertise across our global, multi-disciplined organization and will help us solve problems and continue our forward-looking innovation that impacts patient lives," said Antoinette Gawin, President and Chief Executive Officer, Terumo BCT.
Kunzler holds a Ph.D. in Cell Biology/Neuroscience from the University of Illinois, Chicago. She earned a Master of Science in Toxicology from the University of Florida and an MBA in Healthcare Administration from Benedictine University.
" am a passionate leader with experience in product development, international marketing and business model innovation and quality," Kunzler said. "I'm looking forward to carrying forward Terumo's mission of Contributing to Society through Healthcare. I am enthusiastic about building up and supporting the already highly successful Terumo BCT team while developing innovations to help patients in need."
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers, plasma centers and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.